Biomica, a subsidiary of Evogene, and Lishan Biotech have agreed to a worldwide, exclusive licensing deal for a microbiome-based therapeutic. BMC128, designated as LS-LBP-002 by Lishan, is a first-in-class therapeutic developed by Biomica, designed to enhance anti-tumor immune activity.

Currently, BMC128 is completing a Phase I clinical trial in renal cell carcinoma and non-small cell lung cancer. Early clinical results have been promising, with an excellent safety and tolerability profile as well as early signs of efficacy. A high proportion of patients with previously progressive disease have achieved stable disease during treatment.

Microbiome Therapeutic Explained

Explaining the composition of BMC128, Evogene and Lishan described it as a “live biopharmaceutical consortium.” This effectively means four human gut bacterial strains, with defined functional capabilities. Together, they enhance responses to immunotherapy, and stimulate anti-tumor immune activity.

Dr. Weijie Chen, Chairman of Lishan Biotech, evaluated the results demonstrated by BMC128 to date.

Chen is “impressed by the effects observed with BMC128 in lung and renal cancer patients who had experienced disease progression.” The chairman then added that the therapeutic’s continued success would be “for the benefit of cancer patients worldwide.”

Terms of Biomica and Lishan Pact

Under terms of the agreement, Lishan Biotech assumes responsibility for global clinical development, manufacturing, and commercialization.

Following completion of Phase I, Lishan Biotech plans to advance BMC128 into a Phase II clinical study. Eventually, the company will pursue regulatory filings in China and the United States for future commercialization.

“We look forward to advancing the program through further development and ultimately toward commercialization,” Chen said.

Potential Cancer Breakthrough

Ofer Haviv, CEO of Evogene and Biomica, marked the collaboration as a step forward for difficult-to-treat cancers.

“Lishan Biotech’s strong development capabilities and commitment to innovative microbiome-based therapeutics position this program for meaningful value creation,” Haviv said.

Biomica will be eligible to receive development milestone payments, in addition to royalties on future commercial sales.